Stock Events

Stock Events

Emergent Biosolutions 

$5.94
182
-$0.03-0.5% Thursday 20:00
+$0.02+0.34%Thursday 23:37After hours

Statistics

Day High
5.96
Day Low
5.92
52W High
14.06
52W Low
4.36
Volume
33,427
Avg. Volume
-
Mkt Cap
304.56M
P/E Ratio
-
Dividend Yield
-
Dividend
-

Upcoming

Earnings

11NovExpected
Q4 2024
Q1 2025
Q2 2025
Q3 2025
Q1 2026
Q2 2026
Next
-0.5
0.02
0.54
1.06
Expected EPS
-0.391438
Actual EPS
N/A

Financials

7.08%Profit Margin
Profitable
2020
2021
2022
2023
2024
2025
742.9MRevenue
52.6MNet Income

Analyst Ratings

10.00Average Price Target
The highest estimate is 10.00.
From 2 ratings within the last 6 months. This is not an investment recommendation.
Buy
50%
Hold
0%
Sell
50%

People Also Follow

This list is based on the watchlists of people on Stock Events who follow EBS. It's not an investment recommendation.
NVIDIA
31
NVDA
Amazon
28
AMZN
Microsoft
26
MSFT
Apple
23
AAPL

Competitors

This list is an analysis based on recent market events. It's not an investment recommendation.
Pfizer
PFE
Mkt Cap159.99B
Pfizer competes in the biopharmaceutical sector, developing vaccines and therapeutics similar to Emergent Biosolutions' portfolio.
Johnson & Johnson
JNJ
Mkt Cap651.25B
Johnson & Johnson, through its Janssen Pharmaceuticals division, develops vaccines and drugs that directly compete with Emergent's offerings.
Merck
MRK
Mkt Cap376.37B
Merck & Co. is involved in the creation of vaccines and therapeutic drugs, competing in the same space as Emergent Biosolutions.
GSK
GSK
Mkt Cap104.97B
GlaxoSmithKline focuses on vaccines and pharmaceuticals, making it a direct competitor in Emergent Biosolutions' market.
Sanofi
SNY
Mkt Cap109.86B
Sanofi operates in the pharmaceutical and vaccines market, directly competing with Emergent Biosolutions in several areas.
BioNTech
BNTX
Mkt Cap29.28B
BioNTech SE partners with Pfizer on vaccine development, directly competing with Emergent Biosolutions in the vaccine space.
Novavax
NVAX
Mkt Cap1.47B
Novavax is a direct competitor in the vaccine development sector, particularly in the development of COVID-19 vaccines.
Abbott Laboratories
ABT
Mkt Cap201.83B
Abbott Laboratories competes with Emergent Biosolutions in the diagnostics and medical devices sector, indirectly competing in the broader healthcare market.
Astrazeneca
AZN
Mkt Cap257.42B
AstraZeneca competes in the development of vaccines, including COVID-19 vaccines, positioning it as a competitor to Emergent Biosolutions.
Modine Manufacturing
MOD
Mkt Cap10.5B
Moderna is a key competitor in the mRNA vaccine space, directly competing with Emergent Biosolutions in COVID-19 vaccine development and beyond.

About

Emergent BioSolutions Inc offers public health products to the government and healthcare providers. Company operates in three segments namely Commercial Product, MCM Products, and Services segment. The Commercial Product Segment consisting of Nasal Spray; the MCM Products Segment consisting of Anthrax-MCM products, Smallpox-MCM products and Other Products and the Services Segment consisting of Bioservices portfolio. Geographically, the company operates in United States, Canada, and Others. It derives maximum revenue from United states. The company's products include: NARCAN Nasal Spray, KLOXXADO Nasal Spray, ACAM2000, ANTHRASIL, BAT, BioThrax, CNJ-016, raxibacumab injection, Ebanga, and others.
Show more...
CEO
Joseph C. Papa Jr.
Employees
900
Country
United States
ISIN
US29089Q1058
WKN
000A0LC2W

Listings

F
DE
ER4.F
LSE
GB
0IGA.LSE
STU
DE
ER4.STU
XNYS
US
EBS

0 Comments

Share your thoughts

FAQ

What is Emergent Biosolutions stock price today?▼
The current price of EBS is $5.94 USD — it has decreased by -0.5% in the past 24 hours. Watch Emergent Biosolutions stock price performance more closely on the chart.
What is Emergent Biosolutions stock ticker?▼
Depending on the exchange, the stock ticker may vary. For instance, on XNYS exchange Emergent Biosolutions stocks are traded under the ticker EBS.
Is Emergent Biosolutions stock price growing?▼
EBS stock has risen by +16.93% compared to the previous week, the month change is a -18.74% fall, over the last year Emergent Biosolutions has showed a -29.2% decrease.
What is Emergent Biosolutions market cap?▼
Today Emergent Biosolutions has the market capitalization of 304.56M
When is the next Emergent Biosolutions earnings date?▼
Emergent Biosolutions is going to release the next earnings report on November 11, 2026.
What were Emergent Biosolutions earnings last quarter?▼
EBS earnings for the last quarter are 0.6 USD per share, whereas the estimation was -0.09 USD resulting in a +805.88% surprise. The estimated earnings for the next quarter are N/A USD per share.
What is Emergent Biosolutions revenue for the last year?▼
Emergent Biosolutions revenue for the last year amounts to 742.9M USD.
What is Emergent Biosolutions net income for the last year?▼
EBS net income for the last year is 52.6M USD.
How many employees does Emergent Biosolutions have?▼
As of August 28, 2026, the company has 900 employees.
In which sector is Emergent Biosolutions located?▼
Emergent Biosolutions operates in the Health & Wellness sector.
When did Emergent Biosolutions complete a stock split?▼
Emergent Biosolutions has not had any recent stock splits.
Where is Emergent Biosolutions headquartered?▼
Emergent Biosolutions is headquartered in GAITHERSBURG, United States.